From Nasdaq:

Healthcare is a popular sector among analysts and fund managers for 2024 due to its defensive market nature. However, the Healthcare Select Sector SPDR Fund has already experienced significant growth and may be overpriced at its current 52-week high. This brings the attention to specialized areas of the healthcare sector, particularly biotech, as a potential area for strong investment returns.

Investing in more specialized areas of the healthcare sector, such as individual biotech stocks, may provide higher returns. Companies that own platforms for the development of new drugs, like Intellia Therapeutics, present potential high-risk, high-reward options for investors due to the ability to launch a breakthrough product in gene editing.

While investing in a range of platform stocks may enhance the chances of owning a blockbuster drug, a more focused investment such as Intellia Therapeutics may also be a viable option. This company, along with others like CRISPR Therapeutics, have the potential to make groundbreaking advancements in gene editing and provide a rewarding investment opportunity.



Read more: Healthcare Investing in 2024 | Nasdaq